Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
about
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsThe prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implicationsKRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?The epidermal growth factor receptor conundrum.Alternate dosing of cetuximab for patients with metastatic colorectal cancer.A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.
P2860
Q33809458-6234579A-0C31-4F9C-892D-FAF818D3DE00Q34776118-7DE881D5-E0E9-4B03-98A3-5791E95C80E3Q35069989-FA583DBC-A423-4354-A59C-BF4BE5EDC80EQ35760814-C2516E63-2C83-480C-BCD3-4424D64D6B49Q35942163-2942DA0F-E3FA-42DB-B4E7-63A0839CD755Q36907279-CFD12883-14AD-4CA2-BBBB-258E78560F7FQ36924491-CFCCAADC-9EB1-4A02-A1D2-C545FFADB39BQ38217738-C5691A2F-C3A8-4D32-9C92-BAA69824E21CQ38729418-04126668-FEDA-4D36-BF04-69C119C22577Q39435767-6AC3E8DC-4111-4980-B784-5F000CB2157EQ43411752-C653D180-B50D-499E-B99D-51C54F30872BQ45343162-8AC53E3A-27CB-4B43-AD82-1D18EE485319
P2860
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@en
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@nl
type
label
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@en
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@nl
prefLabel
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@en
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@nl
P2093
P2860
P356
P1476
Mechanisms of resistance to an ...... metastatic colorectal cancer.
@en
P2093
John Souglakos
Vassilis Georgoulias
Zacharenia Saridaki
P2860
P304
P356
10.3748/WJG.V16.I10.1177
P407
P577
2010-03-01T00:00:00Z